Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Quanyin Hu Clear advanced filters

  • Tyrosinase (TYR) catalyses the two initial steps of melanin synthesis from tyrosine and is a target in developing therapeutics to treat melanin-associated disorders. Here, the authors devise a TYR-based in situ catalytic platform that can generate drugs intracellularly through an endogenous copper-catalysed azide-alkyne cycloaddition reaction, as well as a TYR-catalysed in situ formed proteolysis-targeting chimeras to degrade intracellular TYR protein and decrease melanin synthesis for treating hyperpigmentation.

    • Yawen You
    • Zhaochen Guo
    • Quanyin Hu
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-15

  • Engineered pyroptotic vesicles formed during tumour cell pyroptosis and engineered as personalized tumour vaccines can activate a robust antitumour immune response for post-surgical tumour recurrence inhibition.

    • Zhaoting Li
    • Yixin Wang
    • Quanyin Hu
    Research
    Nature Nanotechnology
    Volume: 20, P: 1108-1118

  • Platelets can promote cancer progression through either direct and indirect mechanisms, and they can also suppress tumour progression in certain contexts. The authors of this Review discuss how insights on these properties have been leveraged to develop cancer therapies in which platelets are engineered to act as targeted delivery vehicles or as active effector cells, outlining opportunities and challenges for clinical translation.

    • Yu Chen
    • Tyler Wolter
    • Quanyin Hu
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 23, P: 323-340

  • Activation of ESCRT-mediated cell membrane repair can reduce the extent of tumor cell pyroptosis. Here the authors develop two formulations (an injectable hydrogel and a cell patch) for the sustained release of a Gasdermin-D bacteria-based delivery system and of biodegradable nanoparticles loaded with an ESCRT inhibitor, triggering pyroptosis and antitumor immune responses in preclinical cancer models.

    • Zhaoting Li
    • Fanyi Mo
    • Quanyin Hu
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-15

  • Increased density of tumor associated macrophages has been correlated with tumor recurrence following surgery. Here the authors design an alginate-based hydrogel encapsulating anti-PD-1-conjugated platelets and nanoparticles loaded with the macrophage-depleting CSF-1R inhibitor pexidartinib, showing inhibition of post-surgery tumor recurrence in preclinical models.

    • Zhaoting Li
    • Yingyue Ding
    • Quanyin Hu
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-15

  • The use of inorganic carriers for drug delivery is often limited by toxicity and persistence of inorganic species in the body. Here, the authors report the use of nanocarriers with a liquid-phase eutectic gallium-indium core capable of delivering doxorubicin and subsequently fusing and degrading under mildly acidic conditions.

    • Yue Lu
    • Quanyin Hu
    • Zhen Gu
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-10

  • Cells can be engineered to modify their function and behaviour for therapeutic and diagnostic applications. This Review discusses biological, genetic and materials-based engineering approaches for both mammalian and bacterial cells, outlining key design strategies and applications of engineered cell products.

    • Zhaoting Li
    • Yixin Wang
    • Quanyin Hu
    Reviews
    Nature Reviews Bioengineering
    Volume: 2, P: 770-784